Do the potential benefits outweigh the risks? An update on the use of ziconotide in clinical practice

@article{Bckryd2018DoTP,
  title={Do the potential benefits outweigh the risks? An update on the use of ziconotide in clinical practice},
  author={Emmanuel B{\"a}ckryd},
  journal={European Journal of Pain},
  year={2018},
  volume={22}
}
  • E. Bäckryd
  • Published 1 August 2018
  • Medicine
  • European Journal of Pain
Ziconotide is a selective and potent blocker of N‐type voltage‐gated calcium channels. It was approved by the Food and Drug Administration in 2004 and by the European Medicines Agency in 2005 for the treatment of severe chronic pain in patients needing intrathecal analgesia (ITA). The aim of this paper is to provide a practitioner‐oriented, educational, narrative, up‐to‐date review on the use of ziconotide in clinical pain medicine. Of special concern regarding safety is the partial incongruity… 
View on Wiley
liu.diva-portal.org
14 Citations
Background Citations
2
Methods Citations
1

14 Citations

Citation Type

Citation Type

Intrathecal pain management with ziconotide: Time for consensus?
TLDR
Recommendations made by six pain specialists who discussed the rationale for ziconotide intrathecal analgesia (ITA) and the requirement for evidence‐based guidance on its use, from a European perspective are summarized.
Membrane Stabilizer Medications in the Treatment of Chronic Neuropathic Pain: a Comprehensive Review
TLDR
Though there is limited medical literature as to efficacy of any one drug, individualized multimodal therapy can provide significant analgesia to patients with chronic neuropathic pain.
Intrathecal therapy for pain in cancer patients
  • D. Dupoiron
  • Medicine, Biology
    Current opinion in supportive and palliative care
  • 2019
TLDR
All recent recommendations highlight the efficiency of IDDS and propose to use it sooner, and technical innovations include new catheters and anchorage devices for easier placement and a lower rate of complication.
Systemic, Intrathecal, and Intracerebroventricular Antihyperalgesic Effects of the Calcium Channel Blocker CTK 01512-2 Toxin in Persistent Pain Models.
TLDR
Results reinforce the therapeutic potential of CTK 01512-2 to treat persistent pain conditions and offer a perspective to use the systemic route and increase the glial cell viability in the MTT reduction assay, and it may indicate a new approach to managing chronic pain.
Managing Chronic Non-Malignant Pain in the Elderly: Intrathecal Therapy
TLDR
Current knowledge regarding intrathecal opioid therapy is reviewed, focusing particularly on the use of IDD in elderly patients, and the arguments in favor of and against this therapy in elderly Patients are discussed.
Protective effect of a spider recombinant toxin in a murine model of Huntington's disease
Virtual insights on G protein inhibition and ion channel block – a computer-based study
TLDR
The present work focuses on understanding the mechanisms of action of two pharmaceutically relevant inhibitor protein systems and their target protein, the alpha- (α) subunit of a heterotrimeric G protein as well as conotoxins, venoms obtainable from marine cone snails, which can act as blockers of voltage-gated ion channels.
Pharmakologie der Nichtopioidanalgetika
TLDR
The basic pharmacology and main adverse effects of high-dose acetylsalicylic acid, traditional nonsteroidal anti-inflammatory drugs, and coxibs exhibit antipyretic and anti- inflammatory properties.
Ziconotide for spinal cord injury‐related pain
TLDR
This cohort study assessed responder rate and long‐term efficacy of intrathecal ziconotide in patients with pain related to spinal cord injury.
Neurobiological activity of conotoxins via sodium channel modulation.
...
1
2
...

References

SHOWING 1-10 OF 103 REFERENCES
Ziconotide: a clinical update and pharmacologic review
  • J. Pope, T. Deer
  • Medicine, Biology
    Expert opinion on pharmacotherapy
  • 2013
TLDR
Ziconotide is a safe and effective strategy to treat chronic pain, although limitations remain, including a small therapeutic window, and low starting doses and slow incremental increases and long titration intervals may improve tolerability.
The Pharmacology of Spinal Opioids and Ziconotide for the Treatment of Non-Cancer Pain
TLDR
Intrathecal therapy has level-one evidence for use for malignant pain and nonmalignant pain, with continued cost savings and improved safety, and a clear appreciation for the pharmacology of commonly employed intrathecal agents is paramount.
Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain
TLDR
Ziconotide is a conopeptide intrathecal analgesic which provides analgesia via binding to N-type voltage-sensitive calcium channels in the spinal cord and is approved by the US FDA for the management of severe chronic pain.
Ziconotide for treatment of severe chronic pain
Acute cardiovascular toxicity of low-dose intrathecal ziconotide.
TLDR
A case where a remarkably short, low-dose exposure to i.t. ziconotide produced severe cardiovascular and neurological impairment reversing over the course of 24 hours is reported.
Intrathecal Ziconotide for Severe Chronic Pain: Safety and Tolerability Results of an Open-Label, Long-Term Trial
TLDR
Long-term IT ziconotide is an option for patients with severe, refractory chronic pain and safety and effectiveness assessments included the Visual Analog Scale of Pain Intensity.
Intrathecal Therapy: What Has Changed With the Introduction of Ziconotide
TLDR
This review shall examine recommendations of the polyanalgesic initiative, which are tailored toward those practicing intrathecal analgesia in the U.S., and discuss how they should be implemented in Europe, where the healthcare systems and regulations of the medical authorities are different.
Intrathecal Ziconotide: A Review of Its Use in Patients with Chronic Pain Refractory to Other Systemic or Intrathecal Analgesics
TLDR
Intrathecal ziconotide provides a treatment option for patients with severe, unremitting pain who have failed to respond to other intensive analgesic regimens and for enhancing its efficacy and tolerability.
The Relationship Between the Mechanisms of Action and Safety Profiles of Intrathecal Morphine and Ziconotide: A Review of the Literature.
TLDR
Potentially severe and clinically relevant adverse events (AEs) associated with IT morphine include respiratory depression, tolerance, and granuloma formulation, whereas IT ziconotide is associated with neuropsychiatric AEs, such as cognitive impairment, hallucinations, and changes in mood or consciousness, particularly with high doses and rapid titration.
Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol.
...
1
2
3
4
5
...